Abstract
GM-CSF (granulocyte-macrophage-derived colony-stimulating factor) is a differentiation agent that stimulates bone marrow activity in patients receiving chemotherapy. GM-CSF (1 μg/ml daily for 10 days), administered intralesionally, was evaluated to determine whether it would restore a more differentiated phenotype to an anaplastic, rapidly growing, hormone-independent variant (R3327 MAT-LyLu) of the Dunning prostatic adenocarcinoma. Immunohistology was used to quantitate the expression of epithelial growth factor receptors (rEGF) and the tissue testosterone content. GM-CSF therapy significantly (P<0.05) restored rEGF expression and tissue testosterone to levels associated with better differentiated, slower growing, androgen-dependent Dunning variants (R3327 H and G). GM-CSF may have a role in treatment of prostatic cancers by promoting androgen and epithelial growth factor regulation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 309-312 |
| Number of pages | 4 |
| Journal | Urological Research |
| Volume | 19 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 1991 |
| Externally published | Yes |
Fingerprint
Keywords
- Differentiation
- Dunning tumor
- GM-CSF
- Growth factors
- Prostate
- Therapy
ASJC Scopus subject areas
- Urology
Cite this
GM-CSF restoration of a differentiated (growth factor-regulated) phenotype in an anaplastic tumor. / Rubenstein, M.; Shaw, M.; Targonski, P.; McKiel, C. F.; Dubin, A.; Guinan, P.
In: Urological Research, Vol. 19, No. 5, 09.1991, p. 309-312.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - GM-CSF restoration of a differentiated (growth factor-regulated) phenotype in an anaplastic tumor
AU - Rubenstein, M.
AU - Shaw, M.
AU - Targonski, P.
AU - McKiel, C. F.
AU - Dubin, A.
AU - Guinan, P.
PY - 1991/9
Y1 - 1991/9
N2 - GM-CSF (granulocyte-macrophage-derived colony-stimulating factor) is a differentiation agent that stimulates bone marrow activity in patients receiving chemotherapy. GM-CSF (1 μg/ml daily for 10 days), administered intralesionally, was evaluated to determine whether it would restore a more differentiated phenotype to an anaplastic, rapidly growing, hormone-independent variant (R3327 MAT-LyLu) of the Dunning prostatic adenocarcinoma. Immunohistology was used to quantitate the expression of epithelial growth factor receptors (rEGF) and the tissue testosterone content. GM-CSF therapy significantly (P<0.05) restored rEGF expression and tissue testosterone to levels associated with better differentiated, slower growing, androgen-dependent Dunning variants (R3327 H and G). GM-CSF may have a role in treatment of prostatic cancers by promoting androgen and epithelial growth factor regulation.
AB - GM-CSF (granulocyte-macrophage-derived colony-stimulating factor) is a differentiation agent that stimulates bone marrow activity in patients receiving chemotherapy. GM-CSF (1 μg/ml daily for 10 days), administered intralesionally, was evaluated to determine whether it would restore a more differentiated phenotype to an anaplastic, rapidly growing, hormone-independent variant (R3327 MAT-LyLu) of the Dunning prostatic adenocarcinoma. Immunohistology was used to quantitate the expression of epithelial growth factor receptors (rEGF) and the tissue testosterone content. GM-CSF therapy significantly (P<0.05) restored rEGF expression and tissue testosterone to levels associated with better differentiated, slower growing, androgen-dependent Dunning variants (R3327 H and G). GM-CSF may have a role in treatment of prostatic cancers by promoting androgen and epithelial growth factor regulation.
KW - Differentiation
KW - Dunning tumor
KW - GM-CSF
KW - Growth factors
KW - Prostate
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=0025787553&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025787553&partnerID=8YFLogxK
U2 - 10.1007/BF00299066
DO - 10.1007/BF00299066
M3 - Article
C2 - 1949430
AN - SCOPUS:0025787553
VL - 19
SP - 309
EP - 312
JO - Urolithiasis
JF - Urolithiasis
SN - 2194-7228
IS - 5
ER -